Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, with patients whose tumors bear NTRK fusions responding well and durably to this targeted therapy.
from Cancer via ola Kala on Inoreader http://ift.tt/1Rnt0yy
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου